Edition:
United States

Abbott Laboratories (ABT)

ABT on New York Consolidated

43.68USD
23 May 2017
Change (% chg)

$-0.05 (-0.11%)
Prev Close
$43.73
Open
$43.71
Day's High
$44.17
Day's Low
$43.62
Volume
4,672,763
Avg. Vol
7,368,759
52-wk High
$45.84
52-wk Low
$36.76

ABT

Chart for ABT

About

Abbott Laboratories is engaged in the discovery, development, manufacture and sale of a range of healthcare products. The Company operates through four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products and Vascular Products. Its Established Pharmaceutical Products include a range of branded... (more)

Overall

Beta: 1.43
Market Cap(Mil.): $75,686.30
Shares Outstanding(Mil.): 1,728.00
Dividend: 0.26
Yield (%): 2.42

Financials

  ABT Industry Sector
P/E (TTM): 48.62 29.41 30.38
EPS (TTM): 0.90 -- --
ROI: -- 13.85 13.36
ROE: -- 14.79 14.50

BRIEF-Abbott reports CE Mark for tacticath contact force ablation catheter

* Abbott announces CE Mark for tacticath™ contact force ablation catheter, sensor enabled™

May 09 2017

BRIEF-Abbott announces CE Mark and first use of the world's first smartphone compatible insertable cardiac monitor

* Abbott announces CE mark and first use of the world's first smartphone compatible insertable cardiac monitor

May 08 2017

China's richest man deepens sports foray with global marathons deal

BEIJING China's Dalian Wanda Group, controlled by the country's richest man Wang Jianlin, has signed a deal to sponsor races with the world's top organizer, Abbott World Marathon Majors (WMM), the latest move by Wanda to expand its global sports business.

Apr 26 2017

CORRECTED-OFFICIAL-China's richest man deepens sports foray with global marathons deal

BEIJING, April 26 China's Dalian Wanda Group, controlled by the country's richest man Wang Jianlin, has signed a deal to sponsor races with the world's top organizer, Abbott World Marathon Majors (WMM), the latest move by Wanda to expand its global sports business.

Apr 26 2017

BRIEF-Abbott Laboratories develops 2 new science-based nutrition drinks for patients undergoing surgery

* Abbott Laboratories - developed two new science-based nutrition drinks for patients undergoing surgery Source text for Eikon: Further company coverage:

Apr 26 2017

Abbott sees Alere as challenging 'fixer-upper' after revised deal

Abbott Laboratories said it was looking to close the recently revised deal to buy Alere Inc in the coming months, calling the diagnostics company "a bit of a fixer-upper".

Apr 19 2017

UPDATE 3-Abbott sees Alere as challenging "fixer-upper" after revised deal

* Closing of new Alere deal is a little unpredictable - CFO (Adds conference call details; Updates shares)

Apr 19 2017

BRIEF-Abbott CFO says "We're not going to really be in a good position to give a lot of detailed guidance (on Alere) until minimum Q4" - Conf Call

* Abbott CEO says "the acquisition of Alere will significantly expand our diagnostics presence and leadership in that space" - Conf Call

Apr 19 2017

Abbott posts 29.7 pct rise in quarterly sales

April 19 Diversified healthcare company Abbott Laboratories reported a 29.7 percent rise in quarterly sales on Wednesday, driven by its $25 billion acquisition of St. Jude Medical.

Apr 19 2017

BRIEF-Abbott Q1 adjusted earnings per share $0.48 from continuing operations

* Q1 adjusted earnings per share $0.48 from continuing operations

Apr 19 2017

More From Around the Web

Competitors

  Price Chg
Johnson & Johnson (JNJ.N) $127.52 +0.26
Pfizer Inc. (PFE.N) $32.14 +0.02
Novartis AG (NOVN.S) CHF79.05 -0.35
Merck & Co., Inc. (MRK.N) $64.55 +0.51
Sanofi SA (SASY.PA) €87.82 +0.07
AstraZeneca plc (AZN.L) 5,141.00 +11.00
GlaxoSmithKline plc (GSK.L) 1,629.50 -12.50
Eli Lilly and Co (LLY.N) $77.99 +1.01
Amgen, Inc. (AMGN.OQ) $154.07 +1.05
Boston Scientific Corporation (BSX.N) $26.67 -0.13

Earnings vs. Estimates